<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="was not found. One case with no prior history of" exact="oseltamivir" post="treatment possessed H275Y mutated virus in neuraminidase (NA), which"/>
 <result pre="H275Y mutated virus in neuraminidase (NA), which confers resistance to" exact="oseltamivir" post="and peramivir with elevated IC50 values. The full genome"/>
 <result pre="virus in neuraminidase (NA), which confers resistance to oseltamivir and" exact="peramivir" post="with elevated IC50 values. The full genome sequence of"/>
 <result pre="showed no mutations in neuraminidase (NA), which indicated susceptibility to" exact="oseltamivir" post="[8]. In July 2017, severe cases of influenza A(H1N1)pdm09"/>
 <result pre="for the mutation on NA gene that confers resistance to" exact="oseltamivir" post="was performed on the isolates using fluorescent-labeled chimeric RNA-DNA"/>
 <result pre="assay (NA inhibition assay) against four kinds of neuraminidase inhibitors," exact="oseltamivir" post="(Sequoia Research Products Ltd., Pangbourne, UK), zanamivir (Sequoia Research"/>
 <result pre="of neuraminidase inhibitors, oseltamivir (Sequoia Research Products Ltd., Pangbourne, UK)," exact="zanamivir" post="(Sequoia Research Products Ltd.), peramivir (Shionogi &amp;amp; Co., Ltd.,"/>
 <result pre="Research Products Ltd., Pangbourne, UK), zanamivir (Sequoia Research Products Ltd.)," exact="peramivir" post="(Shionogi &amp;amp; Co., Ltd., Osaka, Japan), and laninamivir (Daiichi"/>
 <result pre="Â°C, headache, runny nose, and myalgia. He did not receive" exact="oseltamivir" post="treatment prior to and after the medical visit. His"/>
 <result pre="the H275Y mutant A(H1N1)pdm09 virus has elevated IC50 value for" exact="oseltamivir" post="(301.5 nM with 198-fold increase) and peramivir (21.9 nM"/>
 <result pre="IC50 value for oseltamivir (301.5 nM with 198-fold increase) and" exact="peramivir" post="(21.9 nM with 274-fold increase) but not for zanamivir"/>
 <result pre="and peramivir (21.9 nM with 274-fold increase) but not for" exact="zanamivir" post="(0.58 nM with 0.9-fold difference) and laninamivir (0.72 nM"/>
 <result pre="of the reference drug-sensitive strain A/Perth/265/2009 (275H), indicating resistance to" exact="oseltamivir" post="and peramivir with highly reduced inhibition. All of the"/>
 <result pre="reference drug-sensitive strain A/Perth/265/2009 (275H), indicating resistance to oseltamivir and" exact="peramivir" post="with highly reduced inhibition. All of the remaining A(H1N1)pdm09"/>
 <result pre="with the reference strain A/Perth/265/2009 (275H) with IC50 values for" exact="oseltamivir" post="being 1.52nM, peramivir 0.08nM, zanamivir 0.62nM, laninamivir 0.27nM. Genetic"/>
 <result pre="strain A/Perth/265/2009 (275H) with IC50 values for oseltamivir being 1.52nM," exact="peramivir" post="0.08nM, zanamivir 0.62nM, laninamivir 0.27nM. Genetic characterization of HA"/>
 <result pre="(275H) with IC50 values for oseltamivir being 1.52nM, peramivir 0.08nM," exact="zanamivir" post="0.62nM, laninamivir 0.27nM. Genetic characterization of HA and NA"/>
 <result pre="27 in the M2 segment, which confers drug resistance to" exact="amantadine" post="[25]. Of note, the first oseltamivir-resistant strain in Myanmar"/>
 <result pre="the first case of oseltamivir-resistant virus in Myanmar without prior" exact="oseltamivir" post="treatment was detected in our study. In Myanmar, the"/>
 <result pre="for decades [25]. M2 gene mutations associated with resistance to" exact="amantadine" post="were found in only about 1% of V27A mutations"/>
 <result pre="of a H275Y mutation in NA that confer resistant to" exact="oseltamivir" post="from an influenza A(H1N1)pdm09 isolate in community samples of"/>
 <result pre="showed the S31N mutation in M2 that conferred resistance to" exact="amantadine" post="[8]. Oseltamivir was not previously used for the treatment"/>
 <result pre="were detected in community settings with no known exposure to" exact="oseltamivir" post="and the resistant virus spread within the community even"/>
 <result pre="high fold-increase in IC50 (198 and 274) to two NAIs," exact="oseltamivir" post="and peramivir. Global analysis on the susceptibility of human"/>
 <result pre="substitution was H275Y in A(H1N1)pdm09 viruses, which confers HRI by" exact="oseltamivir" post="and peramivir [41] without affecting the susceptibility to zanamivir"/>
 <result pre="H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and" exact="peramivir" post="[41] without affecting the susceptibility to zanamivir and laninamivir"/>
 <result pre="by oseltamivir and peramivir [41] without affecting the susceptibility to" exact="zanamivir" post="and laninamivir [42]. Despite the low prevalence of oseltamivir-resistance"/>
 <result pre="https://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance_influenza/en/ 12SuzukiY, SaitoR, SatoI, ZaraketH, NishikawaM, TamuraT, et al.Identification of" exact="oseltamivir" post="resistance among pandemic and seasonal influenza A (H1N1) viruses"/>
 <result pre="and Singapore of a novel influenza A(H1N1)2009 variant with reduced" exact="oseltamivir" post="and zanamivir sensitivity due to a S247N neuraminidase mutation."/>
 <result pre="of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and" exact="zanamivir" post="sensitivity due to a S247N neuraminidase mutation. Euro Surveill."/>
</results>
